At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
In Brief
A Phase 2 clinical trial evaluating Placebo and NBI-1065846 for Anhedonia and Major Depressive Disorder. Completed, enrolled 93 participants across 23 sites in 2 countries.
Detailed Summary
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnhedonia, Major Depressive Disorder
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedDec 2021
Primary CompletionJul 2023
Study CompletionSep 2023
TodayJul 2026
First PostedDec 21, 2021
Enrollment StartNov 30, 2021
Primary CompletionJul 7, 2023
Study CompletionSep 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.5 years ago
Interventions
Placebodrug
Tablets for oral administration
NBI-1065846drug
Tablets for oral administration